Serum Levels of ECP, MBP, and EDN in Patients with Cutaneous Melanoma and Their Relationship with Distant Metastasis and Disease Stage
Project no. 31944 · Status: Kapanmış (Yayın bekleniyor) · 2024
Summary
<p>Cutaneous melanoma is a type of cancer with increasing incidence worldwide due to rising UV exposure. While it accounts for only 4% of skin cancers, it is the leading cause of death related to skin malignancies. After the surgical excision of melanoma, sentinel lymph node (SLN) sampling is performed in patients meeting specific criteria. For high-risk patients, advanced imaging techniques are used to detect distant metastases, and the disease stage is determined accordingly. Established prognostic markers in melanoma, in addition to the TNM staging system, include LDH (lactate dehydrogenase) and performance status. Tumor markers such as S100 B protein and melanoma-inhibiting activity (MIA) protein are primarily utilized to detect disease progression but are not directly associated with prognosis. There is a need for new serum markers that can predict prognosis and disease progression in melanoma. Various studies have shown that eosinophil levels are linked to prognosis in different tumor entities. While the role of eosinophilic cationic protein (ECP) in cancer progression or rejection is not yet fully understood, it is thought to have potential as a novel independent prognostic biomarker in melanoma.</p><p>The aim of this study is to evaluate serum levels of ECP, EDN, and MBP in patients with cutaneous melanoma and to investigate their relationship with cancer stage, regional lymph node involvement, and distant metastases. This study seeks to explore the potential of eosinophil granule proteins as predictive markers for disease progression in melanoma.</p>